ITGAV and non-small cell lung carcinoma: First, to confirm the therapeutic potency of cRGDfK as an integrin αVβ3 antagonist in NSCLC cells, we checked the mRNA expression of ITGAV and ITGB3 encoding integrin αV and integrin β3, respectively.